Poster #S244 CONSULTANT PSYCHIATRISTS' PERSPECTIVES REGARDING ANTIPSYCHOTIC DOSE CHOICE AND PLASMA CONCENTRATION THERAPEUTIC DRUG MONITORING

Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study

“…Clinicians may have been inadvertently unaware that the results were available. Alternatively, clinicians’ negative attitudes and expectations regarding antipsychotic TDM or the perceived barriers (Patel et al, 2014b) may account for their reluctance to check the results. This reluctance may have been the result of: (a) a perceived lack of clinical indication, given the modest doses used by collaborating clinicians to warrant the need for TDM; and/or (b) that current schizophrenia guidelines do not recommend the use of TDM for olanzapine or risperidone (Buchanan et al, 2010; Hasan et al, 2012).…”

“…Currently, clozapine is the only SGA for which TDM is more routinely used in clinical practice in the UK, despite psychiatrists holding mainly positive attitudes to TDM for other SGAs (Best-Shaw et al, 2014;Conca et al, 2011;Patel et al, 2014b). This may be a result of weak evidence that TDM can improve clinical outcomes for other SGAs as compared with clozapine (Lopez and Kane, 2013).…”

“…Likely future use of antipsychotic TDM has been found to be influenced by psychiatrists’ attitudes and perceived potential barriers (Patel et al, 2014b), which include the strength of the evidence base, difficulty in interpreting TDM results and patients’ acceptance of TDM methods (Best-Shaw et al, 2014). Currently, clozapine is the only SGA for which TDM is more routinely used in clinical practice in the UK, despite psychiatrists holding mainly positive attitudes to TDM for other SGAs (Best-Shaw et al, 2014; Conca et al, 2011; Patel et al, 2014b). This may be a result of weak evidence that TDM can improve clinical outcomes for other SGAs as compared with clozapine (Lopez and Kane, 2013).…”